scholarly journals A Malaysian retrospective study of acupuncture-assisted anesthesia in breast lump excision

2020 ◽  
pp. 096452842092030
Author(s):  
Ju-Ying Ang ◽  
Kavita Bhojwani ◽  
Huan-Keat Chan ◽  
Ai-Chen Chan
Keyword(s):  
Electrical Stimulation ◽  
Retrospective Study ◽  
Adverse Events ◽  
Medical Records ◽  
Large Scale ◽  
Controlled Study ◽  
Acupuncture Points ◽  
Breast Lump ◽  
Randomized Controlled ◽  
Median Pain

Introduction The objective of this retrospective study was to evaluate the effectiveness and safety of acupuncture-assisted anesthesia (AAA) in breast lump excision. Methods The medical records of all patients who underwent breast lump excision under AAA in combination with electrical stimulation at traditional acupuncture points in 2016 were examined. All of them (n = 17) received electrostimulation (2–4 Hz) using single needles inserted at bilateral LI4 and PC6. They also underwent insertion of four acupuncture needles at the lump site, which were electrically stimulated at 30 Hz frequency. Results All surgical procedures were successful with minimal use of analgesics and local anesthetic. The median pain score reported was 1/10 (interquartile range (IQR) = 2/10) at the first hour, and slightly increased to 2/10 (IQR = 2/10) between 24 and 48 h of the surgery. No major postoperative adverse events were documented, except for drowsiness in one case. Conclusion AAA was found to be generally safe and effective for anaesthesia and analgesia in breast lump excision. However, a large-scale randomized controlled study is required to verify the findings.

scholarly journals Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Saori Fukui ◽  
Mitsuru Seki ◽  
Takaomi Minami ◽  
Kazuhiko Kotani ◽  
Kensuke Oka ◽  
...  
Keyword(s):  
Kawasaki Disease ◽  
Adverse Events ◽  
Intravenous Immunoglobulin ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Randomized Controlled ◽  
Link Type ◽  
Cell Counts ◽  
Infusion Speed ◽  
Ivig Administration

Abstract Background High-dose intravenous immunoglobulin (IVIG) is the mainstay of treatment for Kawasaki disease (KD). Usually, 2 g/kg of IVIG is administered over 10–24 h, depending on the institution or physician, but the association between infusion speed and effectiveness has not been reported. In this study, we evaluated the differences in efficacy and safety between two different IVIG administration speeds. Methods This was a multicenter, unblinded, randomized controlled study. Patients newly diagnosed with KD were randomized into two groups: one who received IVIG over 12 h (12H group, double speed), and one that received IVIG over 24 h (24H group, reference speed). The endpoints included the duration of fever, incidence of coronary artery abnormalities (CAAs) and of adverse events. Laboratory data were evaluated before and after IVIG administration. Results A total of 39 patients were enrolled. There was no difference between groups in fever duration after the initiation of IVIG (21 h vs. 21.5 h, p = 0.325), and no patient experienced CAAs. Two adverse events were observed in the 12H group (elevation of aspartate aminotransferase and vomiting), however no severe adverse events requiring treatments or extension of hospital stay were observed in either group. After initial IVIG administration, the change ratio of inflammatory markers, such as white blood cell counts, neutrophils, C-reactive protein, and albumin, did not show significant differences between the two groups. On the other hand, a greater increase of serum immunoglobulin G from its baseline level was observed in the 24H group compared to the 12H group (3037 ± 648 mg/dl vs. 2414 ± 248 mg/dl, p < 0.01). Conclusion The efficacy and safety of IVIG administered over 12 h (double speed) were similar to those administered over 24 h (reference speed). Trial registration University Hospital Medical Information Network (UMIN000014665). Registered 27 July 2014 – Prospectively registered, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000017058

scholarly journals Systematic Review and Meta-Analysis of Randomized Controlled Trials of Xingnaojing Treatment for Stroke

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Weijun Peng ◽  
Jingjing Yang ◽  
Yang Wang ◽  
Weihao Wang ◽  
Jianxia Xu ◽  
...  
Keyword(s):  
Adverse Events ◽  
Randomized Controlled Trials ◽  
Conventional Treatment ◽  
Large Scale ◽  
Data Extraction ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Study Selection ◽  
Mild Impairment

Objective. Xingnaojing injection (XNJ) is a well-known traditional Chinese patent medicine (TCPM) for stroke. The aim of this study is to assess the efficacy of XNJ for stroke including ischemic stroke, intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH).Methods. An extensive search was performed within using eight databases up to November 2013. Randomized controlled trials (RCTs) on XNJ for treatment of stroke were collected. Study selection, data extraction, quality assessment, and meta-analysis were conducted according to the Cochrane standards, and RevMan5.0 was used for meta-analysis.Results. This review included 13 RCTs and a total of 1,514 subjects. The overall methodological quality was poor. The meta-analysis showed that XNJ combined with conventional treatment was more effective for total efficacy, neurological deficit improvement, and reduction of TNF-αlevels compared with those of conventional treatment alone. Three trials reported adverse events, of these one trial reported mild impairment of kidney and liver function, whereas the other two studies failed to report specific adverse events.Conclusion. Despite the limitations of this review, we suggest that XNJ in combination with conventional medicines might be beneficial for the treatment of stroke. Currently there are various methodological problems in the studies. Therefore, high-quality, large-scale RCTs are urgently needed.

scholarly journals Do Herbal Formulas Influence the International Normalized Ratio of Patients Taking Warfarin? A Retrospective Study

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Hsu-Yuan Lu ◽  
Seung-Yeon Cho ◽  
Seong-Uk Park ◽  
Woo-Sang Jung ◽  
Sang-Kwan Moon ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Cardiovascular Diseases ◽  
Adverse Events ◽  
Electronic Medical Records ◽  
Medical Records ◽  
Herbal Medicines ◽  
International Normalized Ratio

Warfarin is a common anticoagulant agent for cardiovascular diseases, and it is known to interact with several foods and drugs. Several studies report an interaction between warfarin and herbal medicines; however, the influence of herbal medicines on the international normalized ratio (INR) is still controversial. We investigated the influence of herbal formulas on INR of patients taking warfarin. We searched electronic medical records of inpatients for INR results. Then, we compared the changes in INR and any adverse events between the group taking herbal formulas and warfarin (herbal group) and another group taking warfarin only (nonherbal group). Eighty-six patients were included; 45 patients were assigned to the herbal group and 41 patients to the nonherbal group. The herbal group had taken the same dose of warfarin for a longer period. The nonherbal group had a slightly higher mean INR value than the herbal group. The ratio of INR less than 2 and greater than 3, the ratio of INR that increased or decreased by one or more compared to the initial INR, and the ratio of adverse events were not significantly different between the two groups. It is suggested that use of herbal formulas may not influence INR value.

scholarly journals Decision aid on breast cancer screening reduces attendance rate: results of a large-scale, randomized, controlled study by the DECIDEO group

Oncotarget ◽  
2016 ◽  
Vol 7 (11) ◽  
pp. 12885-12892 ◽  
Author(s):  
Aurelie Bourmaud ◽  
Patricia Soler-Michel ◽  
Mathieu Oriol ◽  
Véronique Regnier ◽  
Fabien Tinquaut ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Decision Aid ◽  
Large Scale ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Attendance Rate ◽  
Randomized Controlled

scholarly journals A Comparison of Ondansetron and Lidocaine in Reducing Injection Pain of Propofol: A Randomized Controlled Study

2021 ◽  
Author(s):  
Wirat Wasinwong ◽  
Sarocha Termthong ◽  
Prae Plansangkate ◽  
Jutarat Tanasansuttiporn ◽  
Riam Kosem ◽  
...  
Keyword(s):  
Primary Outcome ◽  
Elective Surgery ◽  
Controlled Study ◽  
Injection Pain ◽  
Syringe Pump ◽  
Intravenous Catheter ◽  
Randomized Controlled ◽  
American Society ◽  
American Society Of Anesthesiologists ◽  
Median Pain

Abstract Background Propofol injection pain is common. Previous studies found that ondansetron can also block sodium channels. Objective The primary outcome was the efficacy of ondansetron compared to lidocaine and placebo for the reduction of propofol injection pain. Method This trial was conducted in 240 patients, American Society of Anesthesiologists classification I-III and aged between 18-65 years old, undergoing elective surgery, and having a 20-gauge intravenous catheter at the hand dorsum. Each group of 80 patients received 8 mg of ondansetron in the O Group, 40 mg of lidocaine in the L Group and normal saline in the C Group. The study medications were blindly given then 1 minute later, the propofol was administered via the syringe pump at the rate of 600 ml/hr. for 30 seconds. Thereafter, the syringe pump of propofol was temporarily paused, and the patients were asked to rate his/her pain. Result The incidence of pain was lowest in the L group (66.2%) compared with the O (82.5%) and the C groups (85.0%) (P<0.01). The median pain score in the L, O, and C groups were 2 (0-4), 4 (2-5), and 4.5 (2-6), respectively (P<0.01). The incidences of no pain, mild, moderate, and severe pain were also significantly different in the L group (33.8%, 37.5%, 21.2%, and 7.5%, respectively) compared with those in the O group (17.5%, 31.2%, 31.2%, and 20.0%, respectively) and the C groups (15.0%, 22.5%, 40.0%, and 22.5%, respectively) (P<0.01).. Conclusion Pretreatment with intravenous lidocaine, rather than ondansetron, can reduce the incidence and intensity of propofol-induced pain.

Sign in / Sign up

Export Citation Format

Share Document